S&P 500   3,370.97 (+0.31%)
DOW   28,053.23 (+0.94%)
QQQ   269.41 (-0.33%)
AAPL   445.94 (-1.10%)
MSFT   206.55 (-0.82%)
FB   264.92 (+0.73%)
GOOGL   1,498.05 (+0.08%)
AMZN   3,146.88 (-0.04%)
NVDA   441.36 (-1.17%)
CGC   17.54 (-2.18%)
BABA   252.23 (+1.65%)
TSLA   1,405.29 (-0.94%)
GE   6.87 (+3.00%)
MU   48.71 (-0.90%)
AMD   79.64 (-3.16%)
T   30.49 (+0.96%)
F   7.29 (+2.82%)
ACB   10.07 (-1.47%)
GILD   68.67 (+0.23%)
NFLX   477.77 (-1.16%)
DIS   131.75 (+2.30%)
BAC   27.33 (+2.90%)
BA   185.59 (+3.44%)
S&P 500   3,370.97 (+0.31%)
DOW   28,053.23 (+0.94%)
QQQ   269.41 (-0.33%)
AAPL   445.94 (-1.10%)
MSFT   206.55 (-0.82%)
FB   264.92 (+0.73%)
GOOGL   1,498.05 (+0.08%)
AMZN   3,146.88 (-0.04%)
NVDA   441.36 (-1.17%)
CGC   17.54 (-2.18%)
BABA   252.23 (+1.65%)
TSLA   1,405.29 (-0.94%)
GE   6.87 (+3.00%)
MU   48.71 (-0.90%)
AMD   79.64 (-3.16%)
T   30.49 (+0.96%)
F   7.29 (+2.82%)
ACB   10.07 (-1.47%)
GILD   68.67 (+0.23%)
NFLX   477.77 (-1.16%)
DIS   131.75 (+2.30%)
BAC   27.33 (+2.90%)
BA   185.59 (+3.44%)
S&P 500   3,370.97 (+0.31%)
DOW   28,053.23 (+0.94%)
QQQ   269.41 (-0.33%)
AAPL   445.94 (-1.10%)
MSFT   206.55 (-0.82%)
FB   264.92 (+0.73%)
GOOGL   1,498.05 (+0.08%)
AMZN   3,146.88 (-0.04%)
NVDA   441.36 (-1.17%)
CGC   17.54 (-2.18%)
BABA   252.23 (+1.65%)
TSLA   1,405.29 (-0.94%)
GE   6.87 (+3.00%)
MU   48.71 (-0.90%)
AMD   79.64 (-3.16%)
T   30.49 (+0.96%)
F   7.29 (+2.82%)
ACB   10.07 (-1.47%)
GILD   68.67 (+0.23%)
NFLX   477.77 (-1.16%)
DIS   131.75 (+2.30%)
BAC   27.33 (+2.90%)
BA   185.59 (+3.44%)
S&P 500   3,370.97 (+0.31%)
DOW   28,053.23 (+0.94%)
QQQ   269.41 (-0.33%)
AAPL   445.94 (-1.10%)
MSFT   206.55 (-0.82%)
FB   264.92 (+0.73%)
GOOGL   1,498.05 (+0.08%)
AMZN   3,146.88 (-0.04%)
NVDA   441.36 (-1.17%)
CGC   17.54 (-2.18%)
BABA   252.23 (+1.65%)
TSLA   1,405.29 (-0.94%)
GE   6.87 (+3.00%)
MU   48.71 (-0.90%)
AMD   79.64 (-3.16%)
T   30.49 (+0.96%)
F   7.29 (+2.82%)
ACB   10.07 (-1.47%)
GILD   68.67 (+0.23%)
NFLX   477.77 (-1.16%)
DIS   131.75 (+2.30%)
BAC   27.33 (+2.90%)
BA   185.59 (+3.44%)
Log in

NASDAQ:RCKTRocket Pharmaceuticals Stock Price, Forecast & News

Add
Compare
Today's Range N/A
50-Day Range
$20.50
MA: $23.50
$26.46
52-Week Range N/A
Volume238,008 shs
Average Volume354,790 shs
Market Capitalization$1.46 billion
P/E RatioN/A
Dividend YieldN/A
Beta2.12
Rocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a multi-platform biotechnology company that focuses on developing gene therapies for rare and devastating pediatric diseases. It has clinical-stage lentiviral vector (LVV) programs under clinical testing to treat fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells or promotes the production of faulty blood cells; and leukocyte adhesion deficiency-I, a genetic disorder that causes the immune system to malfunction It also has additional pre-clinical stage LVV programs include pyruvate kinase deficiency, a rare red blood cell autosomal recessive disorder that results in chronic non-spherocytic hemolytic anemia; and infantile malignant osteopetrosis, a genetic disorder characterized by increased bone density and bone mass secondary to impaired bone resorption. In addition, the company has an adeno-associated virus program for Danon disease, a multi-organ lysosomal-associated disorder leading to early death due to heart failure. It has license agreements with Fred Hutchinson Cancer Research Center; Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas (CIEMAT), Centro de Investigacion Biomedica En Red, and Fundacion Instituto de investigacion Sanitaria Fundacion Jimenez Diaz; CIEMAT and UCL Business PLC; The Regents of the University of California; and REGENXBIO Inc. The company also has a research and collaboration agreement with Lund University; and strategic collaboration agreement with Stanford University School of Medicine. Rocket Pharmaceuticals, Inc. is headquartered in New York, New York.
Read More
Rocket Pharmaceuticals logo

Beat the Market (BTM) Rank

Analyst Opinion: 4.5Community Rank: 2.9Dividend Strength: 0.0Insider Behavior: 2.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

2.01 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:RCKT
CUSIPN/A
Phone646-440-9100

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$6.10 per share

Profitability

Net Income$-77,270,000.00

Miscellaneous

Employees33
Market Cap$1.46 billion
Next Earnings Date11/5/2020 (Estimated)
OptionableOptionable
30 days | 90 days | 365 days | Advanced Chart

Receive RCKT News and Ratings via Email

Sign-up to receive the latest news and ratings for RCKT and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Rocket Pharmaceuticals (NASDAQ:RCKT) Frequently Asked Questions

Do Wall Street analysts recommend investors buy shares of Rocket Pharmaceuticals?

9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Rocket Pharmaceuticals in the last year. There are currently 9 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Rocket Pharmaceuticals
.

When is Rocket Pharmaceuticals' next earnings date?

Rocket Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Thursday, November 5th 2020.
View our earnings forecast for Rocket Pharmaceuticals
.

How were Rocket Pharmaceuticals' earnings last quarter?

Rocket Pharmaceuticals Inc (NASDAQ:RCKT) posted its quarterly earnings data on Wednesday, August, 5th. The biotechnology company reported ($0.45) earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of ($0.50) by $0.05.
View Rocket Pharmaceuticals' earnings history
.

What price target have analysts set for RCKT?

9 equities research analysts have issued 12 month target prices for Rocket Pharmaceuticals' stock. Their forecasts range from $33.00 to $43.00. On average, they expect Rocket Pharmaceuticals' stock price to reach $37.33 in the next year.
View analysts' price targets for Rocket Pharmaceuticals
.

Has Rocket Pharmaceuticals been receiving favorable news coverage?

Media coverage about RCKT stock has trended neutral on Tuesday, according to InfoTrie. The research firm scores the sentiment of press coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Rocket Pharmaceuticals earned a media sentiment score of 0.2 on InfoTrie's scale. They also gave news stories about the biotechnology company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the stock's share price in the near future.
View the latest news about Rocket Pharmaceuticals
.

Who are some of Rocket Pharmaceuticals' key competitors?

What other stocks do shareholders of Rocket Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Rocket Pharmaceuticals investors own include Nymox Pharmaceutical (NYMX), Pfizer (PFE), SCYNEXIS (SCYX), Sorrento Therapeutics (SRNE), Inovio Pharmaceuticals (INO), Myovant Sciences (MYOV), Vaxart (VXRT), Amarin (AMRN), Micron Technology (MU) and TG Therapeutics (TGTX).

Who are Rocket Pharmaceuticals' key executives?

Rocket Pharmaceuticals' management team includes the following people:
  • Mr. Gaurav Shah, CEO, Pres & Director (Age 44)
  • Mr. John C. Militello, Controller (Age 46)
  • Ms. Kinnari Patel M.B.A., Pharm.D., PharmD, MBA, COO & Head of Devel. (Age 39)
  • Dr. Claudine Prowse Ph.D., Sr. VP of Corp. Strategy & IRO
  • Mr. Jonathan Schwartz, Chief Medical Officer (Age 55)

What is Rocket Pharmaceuticals' stock symbol?

Rocket Pharmaceuticals trades on the NASDAQ under the ticker symbol "RCKT."

Who are Rocket Pharmaceuticals' major shareholders?

Rocket Pharmaceuticals' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Assenagon Asset Management S.A. (0.89%), Alps Advisors Inc. (0.14%), Swiss National Bank (0.12%), Torray LLC (0.09%), New York State Common Retirement Fund (0.06%) and Quantitative Systematic Strategies LLC (0.05%). Company insiders that own Rocket Pharmaceuticals stock include David P Southwell, Gaurav Shah, Kinnari Patel and Rtw Investments, Lp.
View institutional ownership trends for Rocket Pharmaceuticals
.

Which institutional investors are selling Rocket Pharmaceuticals stock?

RCKT stock was sold by a variety of institutional investors in the last quarter, including UBS Group AG, Alps Advisors Inc., Torray LLC, Comerica Bank, Mitsubishi UFJ Kokusai Asset Management Co. Ltd., and PNC Financial Services Group Inc..
View insider buying and selling activity for Rocket Pharmaceuticals
.

Which institutional investors are buying Rocket Pharmaceuticals stock?

RCKT stock was bought by a variety of institutional investors in the last quarter, including Assenagon Asset Management S.A., Monarch Partners Asset Management LLC, Rafferty Asset Management LLC, State Board of Administration of Florida Retirement System, Quantitative Systematic Strategies LLC, ProShare Advisors LLC, Principal Financial Group Inc., and Leap Investments LP. Company insiders that have bought Rocket Pharmaceuticals stock in the last two years include Kinnari Patel, and Rtw Investments, Lp.
View insider buying and selling activity for Rocket Pharmaceuticals
.

How do I buy shares of Rocket Pharmaceuticals?

Shares of RCKT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

How big of a company is Rocket Pharmaceuticals?

Rocket Pharmaceuticals has a market capitalization of $0.00. The biotechnology company earns $-77,270,000.00 in net income (profit) each year or ($1.58) on an earnings per share basis. Rocket Pharmaceuticals employs 33 workers across the globe.

What is Rocket Pharmaceuticals' official website?

The official website for Rocket Pharmaceuticals is www.rocketpharma.com.

How can I contact Rocket Pharmaceuticals?

Rocket Pharmaceuticals' mailing address is 350 FIFTH AVENUE SUITE 7530, NEW YORK NY, 10118. The biotechnology company can be reached via phone at 646-440-9100 or via email at [email protected]

This page was last updated on 8/11/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.